SCHEMBL5205652

SCHEMBL5205652

Nc1cccnc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 1/20 0.45
CYP3A4 P08684 3/20 0.44
HSP90AB1 P08238 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
RAB9A P51151 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSP90AA1 P07900 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31606910 1.00 CCR9 (0.45) CCR9CYP3A4HSP90AB1TSHRALDH1A1
SCHEMBL12303867 0.83 CCR9 (0.44) CCR9CYP3A4ALDH1A1KDM4EHPGD
SCHEMBL5847190 0.79 L3MBTL1 (0.48) ALDH1A1HPGDMEN1KMT2ARAB9A
SCHEMBL2869404 0.79 DPP4 (0.46) CCR9CYP3A4HSP90AB1TSHRALDH1A1
SCHEMBL7092375 0.78 CNR1 (0.48) DPP4
SCHEMBL3663018 0.76 ALDH1A1 (0.49) CCR9ALDH1A1KDM4EHPGDMEN1
SCHEMBL15674379 0.76 CCR9 (0.49) CCR9ALDH1A1RAB9ANPC1MAPT
SCHEMBL17513266 0.76 DPP4 (0.49) CCR9DPP4L3MBTL1TNKS
SCHEMBL24958263 0.74 HSD11B1 (0.43) CCR9CYP3A4HSP90AB1ALDH1A1KDM4E
SCHEMBL20600145 0.74 SCN9A (0.50) DPP4GRM5NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341793-B1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2007-01-17 EP disclosed
US-20040266799-A1 CRF receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. 2004-12-30 US disclosed
US-6747034-B2 CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME NEUROCRINE BIOSCIENCES, INC. 2004-06-08 US disclosed
US-20020151557-A1 CRF receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266799-A1 CRF receptor antagonists and methods relating thereto CRHR1, CRH, CRHR2 CCR9 520/4885CYP3A4 2658/4885HSP90AB1 661/4885
US-20020151557-A1 CRF receptor antagonists and methods relating thereto CRHR1, CRH, CRHR2 CCR9 520/4885CYP3A4 2658/4885HSP90AB1 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.